Risk factors

Braze eliminated its dual-class stock structure, transitioning voting power and increasing susceptibility to stockholder activism.

The company added general operational risks regarding volume, reputation, and performance. The ABL credit facility terms remain unchanged at a 35 million dollar loan cap.

Real estate loans comprise 79% of total loans held for investment, heavily tying performance to Missouri regional conditions. Commercial real estate concentrations and small-to-mid-sized business lending expose the bank to specific market downturns. Heavy reliance on customer deposits and dividends from subsidiary The Central Trust Bank dictates liquidity. Extensive federal and state banking regulation shapes compliance and capital requirements.

This is a new blank check company with $253 million in trust to pursue an initial business combination. Sponsor holds 26.3% of shares, which become worthless if no deal is completed. Management faces potential conflicts of interest due to outside business commitments and investments.

Chenghe Acquisition III has 18 months from its IPO to complete a business combination using $126.5 million in proceeds. Initial shareholders hold 26.04% of shares and will vote in favor regardless of public votes. The search faces geopolitical risks, U.S.-China relations, and a 10% baseline import tariff rate.

This filing shows no changes to the risk factor section compared to the prior year.

Dakota Gold updated its financial figures, reporting a net loss of $29.5 million and $29.7 million in cash for fiscal 2025. The company expanded its disclosures to include silver alongside gold in its mineral and pricing risks. Outstanding common shares increased to 133.5 million as of March 25, 2026.

The company extended its potential liquidation timeline to October 26, 2026, and updated its voting requirements and going concern warnings.

Dyadic is transitioning from a research-driven firm to a commercially focused enterprise commercializing C1 and Dapibus technologies. The company faces extensive regulatory requirements from the FDA, EMA, and other authorities governing pharmaceutical development. Global economic conditions and capital constraints threaten Dyadic's ability to fund operations and execute its strategy.

Pipeline shifted from itolizumab to new product candidates EQ504 and EQ302, requiring substantial additional capital.

Finward Bancorp faces heightened regulatory oversight and emerging deposit competition from alternative fintech platforms and digital assets like stablecoins. The bank updated its portfolio metrics, showing commercial real estate loans at $555.6 million and fixed-rate loans at $636.9 million.

EDAP faces key risks from cash burn of $20.5 million and debt obligations totaling $24.5 million. Regulatory approval and reimbursement for HIFU technology and Focal One drive commercial success. Transition to a U.S. Domestic Issuer adds significant compliance costs.